Showing results (421-430 of 623) with videos related to
Sort By:
Pageof 63
European Journal of Nuclear Medicine and Molecular Imaging|December 22, 2023
Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [18F]FDG-PET/MRIKai Jannusch, Frederic Dietzel, Nils Martin Bruckmann, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 11, 2025
How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in MiceAtefeh Hosseini, Elias Haj-Yehia, Sebastian Korste, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 3, 2025
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective StudyLena M Unterrainer, Thomas A Hope, Wolfgang P Fendler, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired ResistanceMartin Schuler, Jörg Hense, Kaid Darwiche, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2008
Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidineAndreas K Buck, Ken Herrmann, Christian Meyer Zum Büschenfelde, et al.Plos One|November 27, 2023
Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocolAashna Karbhari, Sherly Mosessian, Kamaxi H Trivedi, et al.European Urology|September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION TrialAndrew J Armstrong, Oliver Sartor, Johann de Bono, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 5, 2025
Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0Emil Novruzov, Gabriel T Sheikh, Eduards Mamlins, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2023
Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinomaMarnix Lam, Etienne Garin, Xavier Palard-Novello, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 10, 2025
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AIDavid Kersting, Katarzyna Borys, Alina Küper, et al.Pageof 63